Download IMS-P21 Discovery of ASP5736, a Novel 5

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Document related concepts

Drug discovery wikipedia, lookup

Neuropharmacology wikipedia, lookup

Neuropsychopharmacology wikipedia, lookup

Drug design wikipedia, lookup

Toxicodynamics wikipedia, lookup

NK1 receptor antagonist wikipedia, lookup

Discovery and development of angiotensin receptor blockers wikipedia, lookup

Cannabinoid receptor antagonist wikipedia, lookup

5-HT3 antagonist wikipedia, lookup

Nicotinic agonist wikipedia, lookup

Psychopharmacology wikipedia, lookup

NMDA receptor wikipedia, lookup

5-HT2C receptor agonist wikipedia, lookup

Discovery and development of antiandrogens wikipedia, lookup

Discovery and development of beta-blockers wikipedia, lookup

CCR5 receptor antagonist wikipedia, lookup

Discovery and development of TRPV1 antagonists wikipedia, lookup

Transcript
IMS-P21 Discovery of ASP5736, a Novel 5-HT5A Receptor Antagonist as an Antipsychotic Drug
○Isao KINOYAMA1, Wataru HAMAGUCHI1, Takehiro MIYAZAKI2, Yohei KOGANEMARU1,
Takuya WASHIO1, Osamu KANEKO1, Yuichiro KAWAMOTO1, Mayako YAMAZAKI1,
Masahiro FUJII1, Toshihiro WATANABE1
1Drug
Discovery Research, Astellas Pharma Inc., 2Development, Astellas Pharma Inc.
The 5-HT5A receptor is a G-protein-coupled seven-transmembrane receptor and expresses predominantly in
neural tissues such as hippocampus, thalamus, amygdala and cerebral cortex with little expression in peripheral
tissues. 5-HT5A KO mice were reported to show increased exploratory activity in response to novel environments.
These observations suggested that the 5-HT5A receptor is involved in regulation of mood, affective disorder, and
cognitive function. Therefore, the 5-HT5A receptor is considered as a potential clinical target for the treatment of
schizophrenia.
As part of our research program directed at the development of new 5-HT5A receptor antagonists, we have
identified ASP5736 as a clinical candidate. ASP5736 is a potent and selective 5-HT5A receptor antagonist, and
showed promising preclinical pharmacological profiles in several animal models of schizophrenia without
specific toxicities such as sedation, catalepsy, or increase in plasma prolactin. In this presentation, we will show
the synthesis, SAR of this novel series of 5-HT5A receptor antagonists, and pharmacological profiles of ASP5736.